Consistent with this, inhibition of mTORC1 by rapamycin promoted the expansion of the CD4+FoxP3+ Treg population and the suppression of Th17 cells, and was capable to decrease disease activity in patients with active SLE (63–65). The gene discussed is FOXP3; the disease is systemic lupus erythematosus.